title: Adenosine diphosphate receptor blockade in coronary intervention.
abstract: Use of adenosine diphosphate (ADP) receptor inhibitors (e.g., thienopyridines, such as clopidogrel or ticlopidine) prior to percutaneous coronary intervention (PCI) reduces the risk of major adverse cardiac events, but important questions remain as to optimal starting and stopping time of administration, optimal dose, and benefit of other agents in conjunction with ADP receptor inhibitors. This article reviews data from recent and ongoing studies that address these issues.
authors.affiliation: Department of Cardiology, University of North Carolina, CB #7075, 338 Burnett-Womack Bldg., Chapel Hill, NC 27599-7075, USA. steven_steinhubl@med.unc.edu
authors.forename: Steven R
authors.initials: SR
authors.lastname: Steinhubl
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D004357:Drug Synergism; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D058921:Purinergic P2Y Receptor Antagonists; D000077144:Clopidogrel; D013988:Ticlopidine